View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry


Innovations in Bioavailability Enhancement with Lipid-based Formulation Technology

  • October 2, 2013


    Eduardo Jule, Ph.D., Senior Manager, Capsugel, shares his thoughts on “Innovations in Bioavailability Enhancement with Lipid-based Formulation Technology”

    Lipid-based formulations (LBF) have become a well-established strategy to improve bioavailability of poorly soluble compounds. With a pipeline of increasingly complex drug candidates with bioavailability challenges, pharmaceutical companies are turning to Capsugel’s Dosage Form Solutions team early in the R&D process for our specialized expertise in LBF design, testing and manufacturing to help accelerate the drug development process and reduce costs to create innovative dosage forms. Our team of formulation scientists provides support in a number of ways, including identifying the best performing LBF using a systematic and rational science-based formulation approach. Securing the right partner and engaging early in the development cycle can be the key to success in LBF development.

    LBF approaches have traditionally been based on “trial and error.” Capsugel DFS addresses this industry-wide problem in a number of ways. Capsugel’s proprietary lipid expert system uses an extensive database of experimentally generated phase diagrams to guide formulation development. In addition, as a founding member of the Lipid Formulation Classification System (LFCS) Consortium, Capsugel leverages key opinion leader insight when evaluating lipid-based formulations, for example, implementing in vitro digestion as part of its LBF design and testing package. This has resulted in the development of lipid-based formulations that have been proven to increase the bioavailability for more than 20 pharmaceutical compounds.

    I will be providing an overview of Capsugel’s DFS technology, an exploration of key physicochemical and biopharmaceutical characteristics to be considered during drug candidate qualification, a key step to selecting the right technology, as well as our strategy to rationally develop, test and recommend LBF through case studies during PODD’s Drug Delivery Formulation Technologies session at 2:00 p.m. on October 10.

    I also invite you to meet with our team on site – including Bend Research, now part of the Capsugel family – to learn more about our expanding suite of bioavailability enhancement technologies.